Brought to you by 
Pfizer, Neurocrine end agreement for indiplon
25 Jan 2012
Executive Summary
Neurocrine Biosciences (neurological therapeutics) and Pfizer have entered into an agreement for the development and marketing of Neurocrine's insomnia compound indiplon (also referred to as NBI-34060). Neurocrine received its right to indiplon under a 1998 sub-license agreement with Dov Pharmaceuticals; Dov had licensed it shortly before, from Wyeth.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer, Neurocrine end agreement for indiplon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice